1-14 of 14
Sergio Marchini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 980: Plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: The MITO-16a/MANGO-OV2a/clinical trial experience

Sergio Marchini, Lara Paracchini, Laura Arenare, Giovanni Scambia, Carmela Pisano, Riccardo Zadro, Laura Mannarino, Annamaria Ferrero, Paolo Chiodini, Daniela Califano, Sandro Pignata, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 980.
https://doi.org/10.1158/1538-7445.AM2024-980
Published: 22 March 2024
View article titled, Abstract 980: Plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: The MITO-16a/MANGO-OV2a/clinical trial experience
Journal Articles

Abstract A062: Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: the MITO-16A/MANGO-OV2A clinical trial experience

Sergio Marchini, Lara Paracchini, Laura Arenare, Giovanni Scambia, Carmela Pisano, Riccardo Zadro, Laura Mannarino, Annamaria Ferrero, Paolo Chiodini, Daniela Califano, Piergiacomo Di Gennaro, Sandro Pignata, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): A062.
https://doi.org/10.1158/1538-7445.OVARIAN23-A062
Published: 04 March 2024
View article titled, Abstract A062: Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: the MITO-16A/MANGO-OV2A clinical trial experience
Journal Articles

Abstract 380: Tumor treating fields enhance cellular drug uptake in mesothelioma cell lines

Monica Lupi, Rosy Amodeo, Lavinia Morosi, Laura Mannarino, Lara Paracchini, Sergio Marchini, Federica Grosso, Roberta Libener, Giovanni L. Ceresoli, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 380.
https://doi.org/10.1158/1538-7445.AM2022-380
Published: 15 June 2022
View article titled, Abstract 380: Tumor treating fields enhance cellular drug uptake in mesothelioma cell lines
Journal Articles

Abstract 1064: Antiproliferative effects of Tumor Treating Fields in human mesothelioma cell lines

Monica Lupi, Federica Mirimao, Nicolò Panini, Greta Piazza, Lara Paracchini, Laura Mannarino, Sergio Marchini, Federica Grosso, Serena Penpa, Antonio Maconi, Giovanni L. Ceresoli, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1064.
https://doi.org/10.1158/1538-7445.AM2021-1064
Published: 01 July 2021
View article titled, Abstract 1064: Antiproliferative effects of Tumor Treating Fields in human mesothelioma cell lines
Journal Articles

The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer

Anil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, R. Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Sergio Marchini, Michael Kahn, Analisa DiFeo
Journal: Cancer Research
Cancer Res (2021) 81 (8): 2044–2055.
https://doi.org/10.1158/0008-5472.CAN-20-2041
Published: 15 April 2021
View article titled, The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer
Open the PDF for The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB-268: Detection of TP53 clonal mutations in PAP test collected up to six years prior to high-grade serous epithelial ovarian cancer diagnosis

Chiara Pesenti, Lara Paracchini, Martina Delle Marchette, Luca Beltrame, Tommaso Bianchi, Tommaso Grassi, Alessandro Buda, Fabio Landoni, Lorenzo Ceppi, Cristina Bosetti, Maria Chiara Paderno, Marco Adorni, Debora Vicini, Patrizia Perego, Biagio Eugenio Leone, Sergio Marchini, Robert Fruscio, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): LB-268.
https://doi.org/10.1158/1538-7445.AM2020-LB-268
Published: 15 August 2020
View article titled, Abstract LB-268: Detection of <em>TP53</em> clonal mutations in PAP test collected up to six years prior to high-grade serous epithelial ovarian cancer diagnosis
Journal Articles

Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents

Ramiro Vázquez, Lucile Astorgues-Xerri, María E. Riveiro, Luca Beltrame, Sergio Marchini, Francesco Bertoni, Ivo Kwee, Mohamed Mohamed, Esteban Cvitkovic, Roberta Frapolli, Maurizio D'Incalci
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3526.
https://doi.org/10.1158/1538-7445.AM2015-3526
Published: 01 August 2015
View article titled, Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents
Journal Articles

Gene expression analysis of Manumycin, a natural farnesyltransferase (FTase) inhibitor, in drug-resistant IL-6-producing myeloma cells.

Sergio Marchini, Eleonora Marrazzo, Riccardo Bonomi, Luigi Mastromauro, Anna Maria Frassanito, Pietro Mariani, T. Fusaro, Massimo Broggini, Franco Dammacco
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 14.
Published: 01 May 2005
View article titled, Gene expression analysis of Manumycin, a natural farnesyltransferase (FTase) inhibitor, in drug-resistant IL-6-producing myeloma cells.
Journal Articles

Matrix Metalloproteinases (MMP9 and MMP2) Induce the Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells: Implications for Ascites Formation

Dorina Belotti, Paola Paganoni, Luigi Manenti, Angela Garofalo, Sergio Marchini, Giulia Taraboletti, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2003) 63 (17): 5224–5229.
Published: 18 September 2003
View article titled, Matrix Metalloproteinases (MMP9 and MMP2) Induce the Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells: <subtitle>Implications for Ascites Formation</subtitle>
Open the PDF for Matrix Metalloproteinases (MMP9 and MMP2) Induce the Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells: <subtitle>Implications for Ascites Formation</subtitle> in another window
Journal Articles

Brostallicin, a Novel Anticancer Agent Whose Activity Is Enhanced upon Binding to Glutathione

Cristina Geroni, Sergio Marchini, Paolo Cozzi, Emanuela Galliera, Enzio Ragg, Tina Colombo, Rosangela Battaglia, Martin Howard, Maurizio D’Incalci, Massimo Broggini
Journal: Cancer Research
Cancer Res (2002) 62 (8): 2332–2336.
Published: 01 April 2002
View article titled, Brostallicin, a Novel Anticancer Agent Whose Activity Is Enhanced upon Binding to Glutathione
Open the PDF for Brostallicin, a Novel Anticancer Agent Whose Activity Is Enhanced upon Binding to Glutathione in another window
Journal Articles

4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms

Sergio Marchini, Giovanna Damia, Massimo Broggini, Giulia Pennella, Marina Ripamonti, Aurelio Marsiglio, Cristina Geroni
Journal: Cancer Research
Cancer Res (2001) 61 (5): 1991–1995.
Published: 01 March 2001
View article titled, 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms
Open the PDF for 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms in another window
Journal Articles

Pharmacological and Toxicological Aspects of 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): A Novel Antineoplastic Agent

Cristina Geroni, Marina Ripamonti, Claudio Arrigoni, Francesco Fiorentini, Laura Capolongo, Donatella Moneta, Sergio Marchini, Paola Della Torre, Clara Albanese, Maria Grazia Lamparelli, Marina Ciomei, Rosaria Rossi, Michele Caruso
Journal: Cancer Research
Cancer Res (2001) 61 (5): 1983–1990.
Published: 01 March 2001
View article titled, Pharmacological and Toxicological Aspects of 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): <subtitle>A Novel Antineoplastic Agent</subtitle>
Open the PDF for Pharmacological and Toxicological Aspects of 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): <subtitle>A Novel Antineoplastic Agent</subtitle> in another window
Journal Articles

p73α Overexpression Is Associated with Resistance to Treatment with DNA-damaging Agents in a Human Ovarian Cancer Cell Line

Faina Vikhanskaya, Sergio Marchini, Mirko Marabese, Emanuela Galliera, Massimo Broggini
Journal: Cancer Research
Cancer Res (2001) 61 (3): 935–938.
Published: 02 February 2001
View article titled, p73α Overexpression Is Associated with Resistance to Treatment with DNA-damaging Agents in a Human Ovarian Cancer Cell Line
Open the PDF for p73α Overexpression Is Associated with Resistance to Treatment with DNA-damaging Agents in a Human Ovarian Cancer Cell Line in another window
Journal Articles

Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer

Paul Fullwood, Sergio Marchini, Janet S. Rader, Alonso Martinez, Donia Macartney, Massimo Broggini, Cristina Morelli, Giuseppe Barbanti-Brodano, Eamonn R. Maher, Farida Latif
Journal: Cancer Research
Cancer Res (1999) 59 (18): 4662–4667.
Published: 15 September 1999
View article titled, Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer
Open the PDF for Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer in another window